Conference Corner: 2 Upcoming Physicians' Education Resource Conferences

7th Annual Multidisciplinary Symposium on Head and Neck Cancer Is Set for Philadelphia

Ezra W. Cohen, MD University of Chicago

The 7th Annual Multidisciplinary Symposium on Head and Neck Cancer will be held on November 19, 2011, at the Hyatt at the Bellevue in Philadelphia, Pennsylvania. The symposium, chaired by Ezra W. Cohen, MD, co-director of the head and neck cancer program at the University of Chicago, will present recent data from international oncology conferences, with a strong emphasis on the use of prognostic/ predictive biomarkers in diagnosis and treatment.

Philadelphia, Pennsylvannia

Faculty members will discuss the latest developments in minimally invasive surgical techniques, new agents and biomarkers under investigation, and state-of-the-art treatment for thyroid cancer and nasopharyngeal carcinoma. This symposium will also feature case-based discussions, questionand- answer sessions with the faculty, and multidisciplinary case management sessions.

School of Breast Oncology

Joyce O’Shaughnessy, MD Baylor Charles A. Sammons Cancer Center

The School of Breast Oncology conference was developed to address the growing specialization in breast cancer and to better advance patient care in practice centers across the country. Led by Joyce O’Shaughnessy, MD, the co-director of breast cancer research at the Baylor Charles A. Sammons Cancer Center in Dallas, Texas, the School of Breast Oncology is a curriculum-based program that focuses exclusively on the clinical management of breast cancer.

Atlanta, Georgia

This 4-day interactive program, which runs from November 3-6, 2011, in Atlanta, Georgia, provides a comprehensive review of the most recent data on aspects of breast cancer biology, diagnostics, prevention, and advances in treatment. The evidence-based curriculum will examine topics such as breast carcinogenesis and the management of high-risk disease, adjuvant chemotherapy and endocrine therapy, imaging modalities and their use, the management of HER2-positive disease, treatment of metastatic disease, and survivorship.